Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Assets Average (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Assets Average for 6 consecutive years, with $1.4 billion as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Assets Average rose 23.02% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Jun 2025, up 23.02%, and an annual FY2025 reading of $1.8 billion, up 60.64% over the prior year.
  • Assets Average was $1.4 billion for Q2 2025 at Avidity Biosciences, down from $1.5 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.5 billion in Q1 2025 and bottomed at $302.6 million in Q2 2021.
  • Average Assets Average over 5 years is $657.1 million, with a median of $563.3 million recorded in 2022.
  • The sharpest move saw Assets Average increased 2.13% in 2021, then skyrocketed 91.32% in 2025.
  • Year by year, Assets Average stood at $426.7 million in 2021, then rose by 25.29% to $534.7 million in 2022, then rose by 12.38% to $600.9 million in 2023, then surged by 91.3% to $1.1 billion in 2024, then grew by 23.02% to $1.4 billion in 2025.
  • Business Quant data shows Assets Average for RNA at $1.4 billion in Q2 2025, $1.5 billion in Q1 2025, and $1.1 billion in Q2 2024.